Cargando…

AKR1B10 expression in benign prostatic hyperplasia and its related mechanism

The aim of the present study was to investigate the expression of aldo-keto reductase family 1 member B10 (AKR1B10) in benign prostatic hyperplasia (BPH) and its related mechanism. In total, 142 BPH patients admitted from March 2017 to March 2019 at the First Hospital of Hunan University of Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Wenjing, Gao, Ya, Zhang, Jiaqi, Zhang, Rong, Chen, Qihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335732/ https://www.ncbi.nlm.nih.gov/pubmed/34434282 http://dx.doi.org/10.3892/ol.2021.12944

Ejemplares similares

Benign Prostatic Hyperplasia
Publicado: (2015)

Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers
por: Laffin, Brian, et al.
Publicado: (2012)

AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas
por: Hojnik, Marko, et al.
Publicado: (2021)

AKR1B10 in gastrointestinal diseases
por: Shen, Yi, et al.
Publicado: (2015)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

The Role of AKR1B10 in Physiology and Pathophysiology
por: Endo, Satoshi, et al.
Publicado: (2021)

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia
por: Hata, Junya, et al.
Publicado: (2023)

Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia
por: Dun, Rong-liang, et al.
Publicado: (2022)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia
por: Roya, Nazmabadi, et al.
Publicado: (2020)

Physical Activity and Benign Prostatic Hyperplasia-Related Outcomes and Nocturia
por: WOLIN, KATHLEEN Y., et al.
Publicado: (2015)

Clinical application of contrast enhanced ultrasound to diagnose benign prostatic hyperplasia
por: Shi, Jingfang, et al.
Publicado: (2014)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?
por: Protopsaltis, Ioannis, et al.
Publicado: (2013)

Assessment of posterior urethra in benign prostatic hyperplasia and after its surgery
por: Agrawal, Vivek, et al.
Publicado: (2020)

Exploring the effects and mechanism of peony pollen in treating benign prostatic hyperplasia
por: Mu, Jun, et al.
Publicado: (2023)

In-silico Investigations of quinine and quinidine as potential Inhibitors of AKR1B1 and AKR1B10: Functional and structural characterization
por: Ejaz, Syeda Abida, et al.
Publicado: (2022)

Three-dimensional measurement and analysis of benign prostatic hyperplasia
por: Feng, Yankun, et al.
Publicado: (2021)

Outcomes of prostate artery embolisation for benign prostatic hyperplasia in 10 cases at Steve Biko Academic Hospital
por: Fischer, Hatty G., et al.
Publicado: (2019)

Morphological Changes of Benign Prostatic Hyperplasia in Culture
por: McMahon, M. J., et al.
Publicado: (1973)

Benign Prostatic Hyperplasia: from Bench to Clinic
por: Yoo, Tag Keun, et al.
Publicado: (2012)

VASTI THERAPY IN THE MANAGEMENT OF BENIGN PROSTATE HYPERPLASIA
por: Gupta, Shivaji, et al.
Publicado: (1997)

Current Laser Treatments for Benign Prostatic Hyperplasia
por: Son, Hwancheol, et al.
Publicado: (2010)

Benign prostatic hyperplasia: An overview of existing treatment
por: Dhingra, Neelima, et al.
Publicado: (2011)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Unsolved Issues in Managing Benign Prostatic Hyperplasia
por: Oh, Seung-June
Publicado: (2013)

Recent advances in treatment for Benign Prostatic Hyperplasia
por: van Rij, Simon, et al.
Publicado: (2015)

Diagnosis and treatment of benign prostate hyperplasia in Asia
por: Foo, Keong Tatt
Publicado: (2015)

Chromosomal aberrations in benign prostatic hyperplasia patients
por: Altok, Muammer, et al.
Publicado: (2016)

Fibronectin Pattern in Benign Hyperplasia and Cancer of the Prostate
por: Janković, Miroslava M., et al.
Publicado: (2008)

Metabolic syndrome and benign prostatic hyperplasia: An update
por: Ngai, Ho-Yin, et al.
Publicado: (2017)

Genetic alterations in benign prostatic hyperplasia patients
por: Mohamed, Hanaa Mahmoud, et al.
Publicado: (2017)

Commentary on “Solving the benign prostatic hyperplasia puzzle”
por: Thomas, Dominique, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8t28h435esak508td8tnog0pmq